EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

5‐fluoro‐deoxyglucose PET/CT response after neoadjuvant chemotherapy predicts long‐term outcomes in soft tissue sarcomas: Results from a prospective trial

Edward Y Cheng, Andrea P Espejo Freire iD, Juan C Manivel, Jerry W Froelich, Brenda J Weigel, Denis R Clohisy, Christian M Ogilvie, Rich Evans, L Chinsoo Cho, Kathryn E Dusenbery, Keith M Skubitz

Cancer · 2025

DOI: 10.1002/cncr.70129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Edward Y Cheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnes…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Sarcoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Rein in Sarcoma Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Only 30%–40% of high‐grade sarcomas respond to initial chemotherapy, which can have significant toxicities. Computed tomography imaging alone has limitations in evaluating treatment response. Imaging with 5‐fluoro‐deoxyglucose–positron emission tomography/computed tomography (FDG‐PET/CT), which evaluates tumor metabolism, offers an alternative. This study examined whether early changes in the maximum standardized uptake value (SUVmax) after neoadjuvant chemotherapy can be used to predict outcomes in high‐grade sarcomas.

Methods

This prospective trial assessed whether changes in the SUVmax after one or four cycles of pegylated‐liposomal doxorubicin plus ifosfamide could predict progression‐free survival (PFS), overall survival (OS), and histologic response. Fifty‐six patients were required for 90% power. Metabolic response was defined as a reduction ≥40% in the SUVmax from baseline after either cycle 1 (delta 1) or cycle 4 (delta 2).

Results

Sixty‐nine patients were enrolled (2006–2013) with a median follow‐up of 8.1 years. The 10‐year PFS rate was 74% versus 42% for delta 1 responders versus nonresponders ( p = .0082), respectively; and 69% versus 33% for delta 2 responders versus nonresponder ( p = .0015), respectively. The 10‐year OS rate was 73% versus 58% for delta 1 responders versus nonresponder ( p = .28), respectively; and 81% versus 37% for delta 2 responders versus nonresponder ( p = .00026), respectively. Of 46 delta 1 nonresponders, 23 met criteria at delta 2. A positron emission tomography response was correlated with histologic necrosis. At last follow‐up, 31 patients (44.9%) were alive and disease free, and 10 (14.5%) were alive with sarcoma. Five patients developed secondary malignancies.

Conclusions

An SUVmax reduction verified on FDG‐PET/CT imaging after neoadjuvant chemotherapy was a strong predictor of long‐term outcomes. Metabolic imaging at treatment completion identified responders, supporting continued therapy in initially nonresponsive patients and guiding personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18SarcomaAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedNeoadjuvant TherapyAdultProspective StudiesAgedDoxorubicinYoung AdultIfosfamideTreatment OutcomeRadiopharmaceuticalsAdolescentProgression-Free SurvivalPrognosis

Stichwörter der Autor:innen

doxorubicinifosfamideneoadjuvant therapypositron emission tomographyprognosissarcomasoft tissue

Substanzen

Fluorodeoxyglucose F18DoxorubicinIfosfamideRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Medicine, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Pathology and Laboratory Medicine, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, USA.
  • Department of Radiology, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Biostatistics Core, The Masonic Cancer Center, The University of Minnesota Medical School, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Andrea P Espejo Freire

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Rein in Sarcoma Foundation
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Cheng, E. Y., Espejo Freire, A. P., Manivel, J. C., Froelich, J. W., Weigel, B. J., Clohisy, D. R., Ogilvie, C. M., Evans, R., Cho, L. C., Dusenbery, K. E., & Skubitz, K. M. (2025). 5‐fluoro‐deoxyglucose PET/CT response after neoadjuvant chemotherapy predicts long‐term outcomes in soft tissue sarcomas: Results from a prospective trial. Cancer. https://doi.org/10.1002/cncr.70129

Vancouver

Cheng EY, Espejo Freire AP, Manivel JC, Froelich JW, Weigel BJ, Clohisy DR, et al. 5‐fluoro‐deoxyglucose PET/CT response after neoadjuvant chemotherapy predicts long‐term outcomes in soft tissue sarcomas: Results from a prospective trial. Cancer. 2025. doi:10.1002/cncr.70129

BibTeX
@article{Cheng2025,
  author = {Cheng, Edward Y and Espejo Freire, Andrea P and Manivel, Juan C and Froelich, Jerry W and Weigel, Brenda J and Clohisy, Denis R and Ogilvie, Christian M and Evans, Rich and Cho, L Chinsoo and Dusenbery, Kathryn E and Skubitz, Keith M},
  title = {5‐fluoro‐deoxyglucose PET/CT response after neoadjuvant chemotherapy predicts long‐term outcomes in soft tissue sarcomas: Results from a prospective trial},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70129}
}
Kostenlos starten →